Considering Biological and Biosimilar Medicines to Treat Rheumatic Diseases – Making the Right Call - Certificate of Completion
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterised by joint swelling, joint tenderness and destruction of synovial joints. The primary goal in treating patients with RA is to maximise long-term quality of life. In recent years, treat-to-target recommendations have been formulated for the management of RA. These targets include either remission (the absence of symptoms or signs of inflammatory disease activity) or low-level disease activity.
This interactive online learning activity is valued at 1 Hour(s) of continuing education.
Adjunct Associate Professor Deborah Rigby
(BPharm, GradDipClinPharm, AdvDipNutrPharm, AdvPracPharm,
AACPA, FPS, FASCP, FACP, FSHP, FAICD
Adjunct Associate Professor, University of Queensland,
Adjunct Associate Professor, Queensland University of Technology
On completion of this program, participants will be better able to:
- Compare and contrast originator biological medicines with their biosimilars in the treatment of rheumatoid arthritis (RA)
- Identify the complexities associated with switching between originator biological medicines and biosimilar medicines in patients with RA
- Implement strategies to reduce the risk of inappropriately switching medicines